Skip to main content

Table 3 Best tumor response in HER2+ breast and gastric patients following treatment with MK-2206 and trastuzumab

From: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Patient Age (years) Sex Diagnosis MK-2206 dose Prior lines of therapy Trastuzumab-free interval (days) Reason for discontinuing prior trastuzumab Time to progressive disease/withdrawal (days) Best response
A 40 to 49 Female Breast cancer 60 mg QOD 5 41 Progressive disease 167 SD (unconfirmed PR)
B 50 to 59 Female Breast cancer 60 mg QOD 4 21 Progressive disease 164 SD
C 50 to 59 Male Gastric cancer 200 mg QW 2 0 Trastuzumab not given 171 SD
D 50 to 59 Female Breast cancer 60 mg QOD 8 48 Unknown 219 SD
E 40 to 49 Female Breast cancer 135 mg QW 5 68 Completed therapy 105 SD
F 50 to 59 Female Breast cancer 60 mg QOD 3 0 Progressive disease 388 (withdraw)a PR
7 50 to 59 Female Breast cancer 135 mg QW 5 28 Progressive disease 106 (withdraw) CR
  1. CR, complete response; HER2, human epidermal growth factor receptor 2; PR, partial response; QOD, every other day; QW, every week; SD, stable disease. aPatient was on trial for 173 days and then continued receiving treatment after database lock for a total of 388 days before withdrawing due to skin rash.